Ramli Suaidah, Sim Maw Shin, Guad Rhanye M, Gopinath Subash C B, Subramaniyan Vetriselvan, Fuloria Shivkanya, Fuloria Neeraj K, Choy Ker Woon, Rana Sohel, Wu Yuan Seng
Department of Pharmaceutical Life Sciences, Faculty of Pharmacy, University of Malaya, Kuala Lumpur 50603, Malaysia.
Department of Biomedical Science and Therapeutics, Faculty of Medicine and Health Science, Universiti Malaysia Sabah, Kota Kinabalu 88400, Sabah, Malaysia.
J Oncol. 2021 Apr 10;2021:5519720. doi: 10.1155/2021/5519720. eCollection 2021.
The rising trend of gastrointestinal (GI) cancer has become a global burden due to its aggressive nature and poor prognosis. Long noncoding RNAs (lncRNAs) have recently been reported to be overexpressed in different GI cancers and may contribute to cancer progression and chemoresistance. They are featured with more than 200 nucleotides, commonly polyadenylated, and lacking an open reading frame. LncRNAs, particularly urothelial carcinoma-associated 1 (), are oncogenes involved in regulating cancer progression, such as cell proliferation, invasion, migration, and chemoresistance, particularly in GI cancer. This review was aimed to present an updated focus on the molecular regulatory roles and patterns of lncRNA in progression and chemoresistance of different GI cancers, as well as deciphering the underlying mechanisms and its interactions with key molecules involved, together with a brief presentation on its diagnostic and prognostic values. The regulatory roles of lncRNA are implicated in esophageal cancer, gastric cancer, pancreatic cancer, hepatobiliary cancer, and colorectal cancer, where they shared similar molecular mechanisms in regulating cancer phenotypes and chemoresistance. Comparatively, gastric cancer is the most intensively studied type in GI cancer. LncRNA is implicated in biological roles of different GI cancers via interactions with various molecules, particularly microRNAs, and signaling pathways. In conclusion, lncRNA is a potential molecular target for GI cancer, which may lead to the development of a novel chemotherapeutic agent. Hence, it also acts as a potential diagnostic and prognostic marker for GI cancer patients.
胃肠道（GI）癌的上升趋势因其侵袭性和预后不良已成为全球负担。最近有报道称，长链非编码RNA（lncRNAs）在不同的胃肠道癌症中过表达，可能促进癌症进展和化疗耐药。它们的特点是有超过200个核苷酸，通常进行多聚腺苷酸化，且缺乏开放阅读框。LncRNAs，特别是尿路上皮癌相关1（），是参与调节癌症进展的癌基因，如细胞增殖、侵袭、迁移和化疗耐药，尤其是在胃肠道癌症中。本综述旨在更新关于lncRNA在不同胃肠道癌症进展和化疗耐药中的分子调节作用和模式的重点内容，同时破译其潜在机制及其与相关关键分子的相互作用，并简要介绍其诊断和预后价值。LncRNA的调节作用涉及食管癌、胃癌、胰腺癌、肝胆癌和结直肠癌，它们在调节癌症表型和化疗耐药方面具有相似的分子机制。相比之下，胃癌是胃肠道癌症中研究最深入的类型。LncRNA通过与各种分子，特别是微小RNA和信号通路相互作用，参与不同胃肠道癌症的生物学作用。总之，lncRNA是胃肠道癌症的一个潜在分子靶点，这可能会导致新型化疗药物的开发。因此，它也可作为胃肠道癌症患者的潜在诊断和预后标志物。
